Good to see you on the CTIX rocket ship jsc52033.
Right now the risk for CTIX is relatively low considering it is a start up bio-tech. The lowest since I've been watching it. (Hard to believe I can say this about a clinical stage bio-tech)
Future trials for all three main drug assets are all but certain. Each a potential share price rally or support agent pre-results, and then a catalyst for the results.
Once those trials are a go, there will be risk for each of them, but each of the three drugs provide safety nets for the other two. If just one makes it to approval it is a big win, they are all potential blockbusters. But before we get those results, there is much to argue for a higher share price.
"Games are won by players who focus on the playing field -- not by those whose eyes are glued to the scoreboard." - Warren Buffett